AstraZeneca at ESMO 2016 Congress

We are excited to present our latest oncology data at one of Europe’s premier oncology conferences, the European Society for Medical Oncology (ESMO) 2016 Congress, live in Copenhagen this week.

Our established heritage in the development and commercialisation of novel oncology medicines is reflected in the depth and breadth of our industry-leading pipeline, and as evidenced by 46 presentations across tumour types and molecules at the ESMO 2016 Congress, we remain committed to following the science with the aim of transforming the cancer treatment paradigm.

Latest from ESMO 2016 Congress

PatientView Survey on use of scientific information

This year we commissioned a survey to better understand how the patient and caregiver community view the landscape of science communications. Reaching 124 patient and caregiver group representatives, we uncovered the increasing need for accessible scientific information for individuals with cancer and their families.

Hormone therapy for metastatic breast cancer: understanding resistance, improving outcomes

John Boyer, Global Medical Affairs Leader, Breast Cancer, AstraZeneca

There are many forms of hormone therapy available for patients with metastatic breast cancer but sometimes tumours can become resistant making some or all of these therapies less effective. Understanding these tumours and their resistance tendencies can influence treatment options and outcomes.

Our pipeline

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.


Projects in our pipeline


New molecular entity approval in the last quarter


New molecular entities in our late-stage pipeline


Redefining the treatment paradigm to eliminate cancer as a cause of death

Page Atlas ID: 1013706.011
Date of next review: October 2017